Retinal pigment epithelial cells (RPE)
Retinal pigment epithelial cells (RPE) derived from iPSCs are a therapy product for age related macular degeneration, an increasing cause of vision loss among people aged 50 and older. Age-related macular degeneration is a paradigm for putting iPSC-based therapy into practice, as evidenced by several ongoing clinical studies. But as of today, none of these approaches resolve the challenge of immune rejection.
In order to solve this mayor issue in developing a therapy for a large number of people, RHEINCELL is forming strong partnerships to convert HLAh iPS cells into clinically applicable RPE cells. In collaboration with renowned national and international partners, RHEINCELL is to utilize its HLAh master cell bank and differentiate these cells into RPE-cells in a clinical-grade manufacturing process. These tissues will be given to the patient in order to replace damaged RPE cells.